15
Participants
Start Date
November 30, 2005
Primary Completion Date
July 31, 2007
Study Completion Date
January 31, 2014
High-dose interleukin-2
Administered days 1-5, and 15-19; the patient will receive 600,000 IU/kg IL-2 by intravenous infusion over 15 minutes every 8 hours (on day 1 and day 15, patients will receive a maximum of 2 doses per day; on all other days in the cycle patients will receive a maximum of 3 doses per day)
genistein
Starting on day 10 and continuing through day 19, genistein will be administered orally at a dose of 600mg/day in two divided doses (i.e. 300mg po bid x 10 days)
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
National Cancer Institute (NCI)
NIH
Northwestern University
OTHER